Our Transactions
Leadership across the largest and most complex situations
Lead Financial Advisor
on its pending ~$26.6 billion sale to
2025
Advising
on its $5.1 billion
sale to
2024
Lead Left Bookrunner
$2.6 billion
Follow-on Offering
2024
Financial Advisor
on its $22.5 billion
acquisition of
2024
Sole Financial Advisor
Ad Hoc Group of First Lien Creditors on
chapter 11 restructuring of $8.1 billion of debt
2024
Lead Financial Advisor
on its €8.0 billion
acquisition of
from Vodafone Group
2024
Advised
on its ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spin-off of
2021
Anouncement Date1
Status
Transaction
Value (M)
January 17, 2025
Pending
Advising WuXi AppTec on the sale of its U.S medical device testing operations to NAMSA
N/A
January 15, 2025
Closed
Acted as an Active Bookrunner on Flowco’s Initial Public Offering
$427
January 14, 2025
Pending
Advising EMCOR Group on its acquisition of Miller Electric
$865
January 13, 2025
Closed
Acted as Lead Global Placement Agent for the fundraise of Hildred Capital’s Fund III
$810
January 10, 2025
Pending
Advising Calpine on its sale to Constellation Energy
~$26,600
January 10, 2025
Pending
Advising Alliance Pharma on its recommended acquisition from DBAY Advisors Limited
£350
January 10, 2025
Pending
Advising RP Management on its sale to Royalty Pharma
~$1,100
January 8, 2025
Pending
Advising Transcarent on its acquisition of Accolade
$621
January 6, 2025
Pending
Advising FuboTV on its business combination with Walt Disney’s Hulu + Live TV vMVPD business
N/A
January 3, 2025
Closed
Advised Nu Skin on the sale of its Mavely business to Later
~250
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.